Summary Box: Merck tweaks R&D, business strategies

AP News
|
Posted: Nov 10, 2011 3:54 PM
Summary Box: Merck tweaks R&D, business strategies

NEW APPROACH: Drugmaker Merck & Co. has retooled research operations to get more bang for the buck, while it's boosting sales of existing drugs, pushing harder into key markets and continuing to rein in spending.

DIVDEND BOOST: For the first time since pulling painkiller Vioxx off the market in 2004, Merck's raising its dividend, by 4 cents to 42 cents this quarter.

ON DECK: Merck has eight new products for which it will seek U.S. approval in 2012 or 2013, others in late testing and a couple that could transform treatment of Alzheimer's disease and hardening of the arteries.